login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
PACIRA BIOSCIENCES INC (PCRX) Stock News
NASDAQ:PCRX -
US6951271005
-
Common Stock
26.13
USD
+0.14 (+0.54%)
Last: 8/27/2025, 4:30:00 PM
26.13
USD
0 (0%)
After Hours:
8/27/2025, 4:30:00 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
PCRX Latest News, Press Relases and Analysis
All
Press Releases
14 days ago - By: Chartmill
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) Emerges as a Strong Value Investing Opportunity
22 days ago - By: The Motley Fool
Pacira (PCRX) Q2 Revenue Rises 1.7%
22 days ago - By: Zacks Investment Research
Here's What Key Metrics Tell Us About Pacira (PCRX) Q2 Earnings
22 days ago - By: Zacks Investment Research
- Mentions:
RCUS
Pacira (PCRX) Tops Q2 Earnings Estimates
22 days ago - By: Pacira BioSciences
Pacira BioSciences Reports Second Quarter 2025 Financial Results
22 days ago - By: Pacira BioSciences
Pacira BioSciences Reports Second Quarter 2025 Financial Results
23 days ago - By: Benzinga
- Mentions:
AFG
CXDO
YUM
PACK
...
Earnings Scheduled For August 5, 2025
23 days ago - By: Benzinga
Insights Ahead: Pacira BioSciences's Quarterly Earnings
a month ago - By: Pacira BioSciences
Pacira to Report Second Quarter 2025 Financial Results on Tuesday August 5, 2025
a month ago - By: Pacira BioSciences
Pacira BioSciences Announces Strategic Collaboration to Significantly Expand ZILRETTA Promotional Efforts
a month ago - By: Shareholders Foundation, Inc.
Investors who lost money with shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) should contact the Shareholders Foundation in connection with Lawsuit
2 months ago - By: Yahoo Finance
Pacira BioSciences Gene Therapy Shows Sustained Knee Osteoarthritis Improvement
2 months ago - By: Pacira BioSciences
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 months ago - By: Pacira BioSciences
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 months ago - By: ACCESS Newswire
- Mentions:
SUI
MODV
IAS
Lifshitz Law PLLC Announces Investigations of Sun Communities, Inc. (NYSE: SUI), Pacira Biosciences, Inc. (NASDAQ: PCRX), ModivCare, Inc. (NASDAQ: MODV), and Integral Ad Science Holding Corp. (NASDAQ: IAS)
2 months ago - By: Pacira BioSciences
Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025
2 months ago - By: Pacira BioSciences
Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025
2 months ago - By: Bragar Eagel & Squire
PACIRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Pacira BioSciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
2 months ago - By: ACCESS Newswire
- Mentions:
BOOM
SUI
MODV
Lifshitz Law PLLC Announces Investigations of DMC Global Inc. (NASDAQ: BOOM), Sun Communities, Inc. (NYSE: SUI), Pacira Biosciences, Inc. (NASDAQ: PCRX), and ModivCare, Inc. (NASDAQ: MODV)
3 months ago - By: Pacira BioSciences
Pacira BioSciences Unveils Three-Year Clinical Data Following a Single Local Administration of Investigational Gene Therapy, PCRX-201, in Patients with Moderate-to-Severe Osteoarthritis of the Knee
3 months ago - By: Pacira BioSciences
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 months ago - By: Pacira BioSciences
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 months ago - By: Grabar Law Office
- Mentions:
DV
NSSC
TMCI
Grabar Law Office Investigates Claims on Behalf of Shareholders of DoubleVerify Holdings, Inc. (NYSE: DV); NAPCO Securities Technologies, Inc. (NASDAQ: NSSC); Pacira Biosciences, Inc. (NASDAQ: PCRX); and Treace Medical Concepts, Inc. (NASDAQ: TMCI)
3 months ago - By: Pacira BioSciences
Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee
4 months ago - By: Pacira BioSciences
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
4 months ago - By: Pacira BioSciences
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
4 months ago - By: Shareholders Foundation, Inc.
Lawsuit for Investors in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) announced by the Shareholders Foundation
4 months ago - By: Zacks Investment Research
- Mentions:
BEAM
ADMA
Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates
4 months ago - By: Zacks Investment Research
Pacira (PCRX) Reports Q1 Earnings: What Key Metrics Have to Say
4 months ago - By: Zacks Investment Research
- Mentions:
ANIP
Pacira (PCRX) Q1 Earnings Surpass Estimates
4 months ago - By: Pacira BioSciences
Pacira BioSciences Reports First Quarter 2025 Financial Results
4 months ago - By: Pacira BioSciences
Pacira BioSciences Reports First Quarter 2025 Financial Results
Please enable JavaScript to continue using this application.